News


All series


All News

In an interview with Targeted Oncology, Pasi A. Jänne, MD, PhD, discussed the current treatment landscape for patients with EGFR-mutant lung cancer, as well as some therapies that currently are under both preclinical and clinical investigation at the Dana-Farber Cancer Institute. He shared advice for community oncologists treating this patient population.

A rolling submission of a New Drug Application for umbralisib has been initiated by drug developer, TG Therapeutics, Inc, which is requesting accelerated approval of the agent from the FDA for the treatment of patients with previously treated marginal zone lymphoma and follicular lymphoma. The company reported in a press release that one application was considered to be acceptable for both drugs and the NDA will be completed in the first half of 2020.<br /> &nbsp;

The FDA has granted priority review status on a supplemental New Drug Application for rucaparib in advanced prostate cancer, according to a release issued by Clovis Oncology.1 The sNDA seeks approval for rucaparib as monotherapy treatment in patients with a BRCA1/2 mutation resulting in recurrent metastatic castrate-resistant prostate cancer. The agency has assigned a Prescription Drug User Fee Act date of May 15, 2020.

Salvage therapy with high&#8208;dose cyclophosphamide showed meaningful clinical activity in a cohort of 6 patients with mantle cell lymphoma who were previously treated with &ge;2 prior lines of therapy and had no other available options. These patients made up 14% of the 42 participants in a phase II study showing similar efficacy in adult patients with other relapsed or refractory B&#8208;cell non&#8208;Hodgkin lymphomas.

To support the commercialization of the blood-based companion diagnostic test Guardant360 companion diagnostic for AMG 510, Guardant Health, Inc, will collaborate with Amgen, developer of AMG 510, and pursue an FDA Pre-Market Approval as a companion diagnostic for AMG 510 in patients with metastatic non&ndash;small cell lung cancer with a&nbsp;KRAS&nbsp;G12C mutation, according to a press release.

In an interview with&nbsp;Targeted Oncology, Andrew J. Cowan, MD, discussed the findings from the first-in-human clinical trial evaluating the combination of a GSI and BCMA CAR T cells in patients with heavily pretreated multiple myeloma. He highlighted the next steps for this research and how he sees CAR T-cell therapy evolving over the coming years.

The supplemental New Drug Application for olaparib, a PARP inhibitor, in combination with bevacizumab has been granted Priority Review by the FDA as maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy, based on the results from the phase III PAOLA-1 trial, according to a press release from AstraZeneca and Merck &amp; Co, Inc.1<br /> &nbsp;

Pralsetinib&nbsp; a highly-selected RET inhibitor, achieved a favorable overall response rate with prolonged durability in patients with RET fusion&ndash;positive non&ndash;small cell lung cancer who were previously treated with platinum-based chemotherapy, according to top-line results from the phase I/II ARROW trial, announced the Blueprint Medicines Corporation in a press release.

In an interview with Targeted Oncology, Simon Rule, MD,&nbsp;discussed the findings from&nbsp;a pooled analysis evaluating the efficacy and safety of using ibrutinib in patients with relapsed/refractory mantle cell lymphoma.&nbsp;He also highlighted other abstracts of interest that were presented during the 2019 American Society of Hematology Annual Meeting that were of interest in the field of mantle cell lymphoma.

The FDA has approved avapritinib for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor who harbor platelet-derived growth factor receptor alpha exon 18 mutation, including PDGFRA D842V mutations. This approval makes avapritinib the first precision medicine therapy for a genomically defined population of patients with GIST, according to a press release from the Blueprint Medicines Corporation.

The phase II TELLOMAK trial, which is evaluating the safety and efficacy of lacutamab in patients with advanced T-cell lymphomas, has been placed on a partial clinical hold by the FDA. The decision was made following discussions regarding Good Manufacturing Practice deficiencies at a subcontractor site that manufacturers the agent&nbsp;in December of 2019, according to a press release from Innate Pharma SA.

The combination of pembrolizumab and chemotherapy improved progression-free survival in patients with small cell lung cancer compared with chemotherapy alone, meeting 1 of the primary end points of the phase III KEYNOTE-604 study, according to a press release from pembrolizumab developer, Merck. Compared with a chemotherapy regimen of either etoposide plus cisplatin or cisplatin alone, the progression-free survival mprovement with pembrolizumab was significant.

Pembrolizumab is now FDA approved for the treatment of patients with Bacillus Calmette-Guerin&ndash;unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

The overall response rate was improved with itacitinib plus corticosteroids compared with placebo plus corticosteroids in patients with treatment-na&iuml;ve acute graft-versus-host disease in the phase III GRAVITAS-301 trial. However, the difference in ORR for the treatment arm compared with the placebo arm was not statistically significant, missing the trial&rsquo;s primary end point.

The Ion Torrent Oncomine Myeloid Research Assay, the first fully-integrated next-generation sequencing platform, will be available in 2020 on the new Ion Torrent Genexus System for research use, according to a press release from Thermo Fisher Scientific. The platform features automated workflow to allow for result delivery within a single day, requiring minimal user intervention and tissue sample input.